No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

9/2

Novatim Immune

Therapeutics

Radiance

Biopharma

KY-0301

MET-EGFR bispecific

nanobody-drug conjugate

Oncology

Solid tumors

Phase 1

1,000

2

9/2

Servier

Ideaya Biosciences

Darovasertib

PKC inhibitor

Oncology

Melanoma

Phase 2/3

210

3

9/2

Novartis

Arrowhead

Pharmaceuticals

ARO-SNCA

SNCA siRNA

Neurology

Parkinson’s disease

Preclinical

200

4

9/3

Novartis

Argo

Biopharmaceutical

BW-00112

ANGPTL3 siRNA

Cardiovascular

diseases

Dyslipidemia

Phase 2

5,000

5

9/3

Avadel

Pharmaceuticals

XWPharma

Valiloxybate

GABAB receptor agonist

Neurology

Narcolepsy, Cataplexy

Phase 2

30

6

9/5

Braveheart Bio

Jiangsu Hengrui
Pharmaceuticals

HRS-1893

Myosin inhibitor

Cardiovascular

diseases

Obstructive hypertrophic

cardiomyopathy

Phase 3

65

7

9/8

Servier

Kaerus Bioscience

KER-0193

BK channel modulator

Neurology

Fragile X syndrome

Phase 1

450

8

9/9

LigaChem

Bioscience

Go Therapeutics

n/d

ADC

Oncology

Solid tumor

Candidates

n/d

9

9/19

VectorY

Therapeutics

Shape TX

SHP-DB1

Deep-brain-penetrating

AAV capsid

Neurology

Huntington’s disease(w/ VTx-003),

Alzheimer’s disease(w/ VTx-005)

Research

1,200

10

9/22

Angelini Pharma

Sovargen

SVG1051

Rapamycin ASO

Neurology

Brain health diseases

Preclinical

550

11

9/24

Jiangsu Hengrui
Pharmaceuticals

Glenmark

Pharmaceuticals

Trastuzumab

Rezetecan

HER2 ADC

Oncology

NSCLC

Marketed

1,090

12

9/25

MSD

Evaxion

EVX-B3

AI-designed vaccine

Respiratory

diseases

COPD

Preclinical

592

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

9/9

Novartis

Tourmaline Bio

Pacibekitug

αIL-6 mAb

Cardiovascular diseases

ASCVD

Phase 2

1,400

2

9/17

Roche

89bio

Pegozafermin

FGF21 analog

Metabolic disorder

MASH

Phase 2

3,500

3

9/22

Pfizer

Metsera

MET-097i

MET-233i

GLP-1 receptor agonist

Amylin receptor agonist

Metabolic disorder

Metabolic disorder

Obesity

Obesity

Phase 2

Phase 1/2

4,900